XML 40 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 7 - Subsequent Events On July 6, 2015, PharmAthene signed a license agreement with Immunovaccine for the exclusive use of the DepoVax^TM vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (“rPA”). Immunovaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse Immunovaccine for their efforts in developing this vaccine. In addition, Immunovaccine will receive annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, Immunovaccine will receive a royalty on sales related to the use of DepoVax^TM.